Skip to main content
Journal cover image

Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.

Publication ,  Journal Article
Taher, T; Fu, Y; Wagner, GS; Goodman, SG; Fresco, C; Granger, CB; Wallentin, L; van de Werf, F; Verheugt, F; Armstrong, PW
Published in: J Am Coll Cardiol
July 7, 2004

OBJECTIVES: The investigators undertook a systematic, comprehensive analysis of the therapeutic response and clinical outcomes of reperfusion therapy for acute ST-segment elevation myocardial infarction (STEMI) in 5,470 patients from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 trial. BACKGROUND: Prompt effective reperfusion therapy for acute STEMI may attenuate major myocardial necrosis. METHODS: We prospectively collected sequential electrocardiographs and clinical data. Aborted myocardial infarction (MI) was defined as maximal creatine kinase < or =2x upper limit of normal coupled with typical evolutionary electrocardiographic changes. RESULTS: Of the patients, 727 (13.3%) had an aborted MI, with the highest frequency (25%) occurring in patients treated <1 h after symptom onset. As compared with MI patients, patients with aborted MI more often had complete ST-segment resolution at 60 min (56.3% vs. 30.2%, p < 0.001) and 180 min (61.5% vs. 53%, p < 0.001); they also had smaller infarct sizes based on QRS score at discharge (2.37 vs. 4.62, p <0.001). Mortality in aborted MI patients compared with those who had true MI was 3.9% versus 4.6% at 30-day and 7.0% versus 7.4% at 1-year. The baseline-adjusted mortality was significantly lower in patients with aborted MI (odds ratio [OR] 0.76, 95% confidence interval [CI] 0.63 to 0.92, p = 0.005 for 30-day and OR 0.70, 95% CI 0.50 to 0.98, p = 0.035 for one year). A very low-risk subset was identified with > or =70% ST-segment resolution at 60 min whose 30-day and 1-year mortality was 1.0% and 2.7%, respectively, compared with 5.9% and 9.3% in aborted MI patients with <70% ST-segment resolution at 60 min (all p < or = 0.002). CONCLUSIONS: Prompt fibrinolytic treatment improved the likelihood of aborted MI. The subgroup with complete 60-min ST-segment resolution had the best clinical outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

July 7, 2004

Volume

44

Issue

1

Start / End Page

38 / 43

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Tenecteplase
  • Prospective Studies
  • Postoperative Complications
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Heart Conduction System
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Taher, T., Fu, Y., Wagner, G. S., Goodman, S. G., Fresco, C., Granger, C. B., … Armstrong, P. W. (2004). Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol, 44(1), 38–43. https://doi.org/10.1016/j.jacc.2004.03.041
Taher, Taha, Yuling Fu, Galen S. Wagner, Shaun G. Goodman, Claudio Fresco, Christopher B. Granger, Lars Wallentin, Frans van de Werf, Freek Verheugt, and Paul W. Armstrong. “Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.J Am Coll Cardiol 44, no. 1 (July 7, 2004): 38–43. https://doi.org/10.1016/j.jacc.2004.03.041.
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol. 2004 Jul 7;44(1):38–43.
Journal cover image

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

July 7, 2004

Volume

44

Issue

1

Start / End Page

38 / 43

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Tenecteplase
  • Prospective Studies
  • Postoperative Complications
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Heart Conduction System